Asia's Innovation Horizon: Insiders Are Optimistic And Wary
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Multinationals are dropping substantial resources in R&D in Asia, but - excluding Japan - Asian countries have yet to create a significant new drug approval, and opinions differ on when strong INDs will begin to appear out of the region